Peak Bio (PKBO) vs. Its Peers Head to Head Survey

Peak Bio (NASDAQ:PKBO) is one of 285 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it compare to its peers? We will compare Peak Bio to related companies based on the strength of its dividends, profitability, institutional ownership, earnings, analyst recommendations, risk and valuation.

Insider & Institutional Ownership

50.5% of shares of all “Biological products, except diagnostic” companies are owned by institutional investors. 19.9% of Peak Bio shares are owned by insiders. Comparatively, 16.2% of shares of all “Biological products, except diagnostic” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Peak Bio and its peers top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Peak Bio	$370,000.00	-$12.83 million	-0.52
Peak Bio Competitors	$547.79 million	-$37.89 million	-21.95

Peak Bio’s peers have higher revenue, but lower earnings than Peak Bio. Peak Bio is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Risk & Volatility

Peak Bio has a beta of 1.56, meaning that its share price is 56% more volatile than the S&P 500. Comparatively, Peak Bio’s peers have a beta of 1.08, meaning that their average share price is 8% more volatile than the S&P 500.

Profitability

This table compares Peak Bio and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Peak Bio	N/A	N/A	-253.92%
Peak Bio Competitors	-4,999.14%	-169.11%	-42.10%

Analyst Recommendations

This is a summary of recent ratings for Peak Bio and its peers, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Peak Bio	0	0	0	0	N/A
Peak Bio Competitors	1608	4833	12564	241	2.59

As a group, “Biological products, except diagnostic” companies have a potential upside of 57.95%. Given Peak Bio’s peers higher possible upside, analysts clearly believe Peak Bio has less favorable growth aspects than its peers.

Summary

Peak Bio beats its peers on 6 of the 10 factors compared.

About Peak Bio

Peak Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of patients with inflammatory, cancer, and rare and specialty diseases. The company's lead product candidate is PHP-303, which is in phase 2 clinical study for the treatment of alpha-1 antitrypsin deficiency and acute respiratory distress syndrome. It also develops Trop2 PH1, an antibody-drug-conjugate for solid tumors. The company was founded in 2020 and is based in Pleasanton, California.